HTR4 and chronic intestinal pseudoobstruction: In line with these findings and in the attempt to search for a treatment that could improve GI conditions and CIPO in NIIDs, we have investigated, in this work, whether modulation of 5-hydroxytryptamine type-4 receptor (5-HT4R) with velusetrag, a highly selective 5-HT4R agonist, could have a positive effect on intestinal abnormalities seen in young SCA7 mice.